ASPIRE model for treating cannabis and other substance use disorders: A novel personalized-medicine framework

Frontiers in Psychiatry

Volumn 5, Issue DEC, 2014, Pages

  Ghitza, Udi E ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Addiction; Addiction treatment; Dependence; Drug abuse; Drug abuse treatment; Substance abuse; Substance abuse treatment; Substance use disorder

Indexed keywords

ACETYLCYSTEINE; CLONIDINE; GABAPENTIN; GUANFACINE; LOFEXIDINE; NABILONE;

ALCOHOLISM; ARTICLE; CANNABIS ADDICTION; CLINICAL EFFECTIVENESS; COCAINE DEPENDENCE; COGNITIVE THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG DEPENDENCE; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; EVIDENCE BASED MEDICINE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL RESEARCH; OPIATE ADDICTION; PATIENT CARE; PERSONALIZED MEDICINE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REINFORCEMENT; RISK ASSESSMENT; SECONDARY PREVENTION; TOBACCO DEPENDENCE; UNITED STATES; WITHDRAWAL SYNDROME;

EID: 84926654396     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2014.00180     Document Type: Article

References (27)

1. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration (2014).
2. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet (2013) 382:1564-74. doi: 10.1016/S0140-6736(13)61530-5
3. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. J Gen Intern Med (2012) 27:1361-7. doi:10.1007/s11606-012-2077-6
4. Légaré F, Witteman HO. Shared decision making: examining key elements and barriers to adoption into routine clinical practice. Health Aff (Millwood) (2013) 32:276-84. doi:10.1377/hlthaff.2012.1078
5. Bradley KA, Kivlahan DR. Bringing patient-centered care to patients with alcohol use disorders. JAMA (2014) 311:1861-2. doi:10.1001/jama.2014.3629
6. Wise RA, Koob GF. The development and maintenance of drug addiction. Neuropsychopharmacology (2014) 39:254-62. doi:10.1038/npp.2013.261
7. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend (2011) 119:123-9. doi:10.1016/j.drugalcdep.2011.06.003
8. Babson KA, Boden MT, Bonn-Miller MO. The impact of perceived sleep quality and sleep efficiency/duration on cannabis use during a self-guided quit attempt. Addict Behav (2013) 38:2707-13. doi:10.1016/j.addbeh.2013.06.012
9. Lee D, Schroeder JR, Karschner EL, Goodwin RS, Hirvonen J, Gorelick DA, et al. Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. Am J Addict (2014) 23:234-42. doi:10.1111/j.1521-0391.2014.12088.x
10. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res (2007) 9:315-27. doi:10.1080/14622200701188919
11. Brooks AT, Wallen GR. Sleep disturbances in individuals with alcohol-related disorders: a review of cognitive-behavioral therapy for insomnia (CBT-I) and associated non-pharmacological therapies. Subst Abuse (2014) 8:55-62. doi:10.4137/SART.S18446
12. Matuskey D, Pittman B, Forselius E, Malison RT, Morgan PT. A multistudy analysis of the effect of early cocaine abstinence on sleep. Drug Alcohol Depend (2011) 115:62-6. doi:10.1016/j.drugalcdep.2010.10.015
13. Oyefeso A, Sedgwick P, Ghodse H. Subjective sleep-wake parameters in treatment-seeking opiate addicts. Drug Alcohol Depend (1997) 48:9-16. doi:10.1016/S0376-8716(97)00097-5
14. Volkow ND, Wang GJ, Tomasi D, Baler RD. Unbalanced neuronal circuits in addiction. Curr Opin Neurobiol (2013) 23:639-48. doi:10.1016/j.conb.2013.01.002
15. Keramati M, Gutkin B. Imbalanced decision hierarchy in addicts emerging from drug-hijacked dopamine spiraling circuit. PLoS One (2013) 8:e61489. doi:10.1371/journal.pone.0061489
16. Blum K, Gardner E, Oscar-Berman M, Gold M. "Liking" and "wanting" linked to reward deficiency syndrome (RDS): hypothesizing differential responsivity in brain reward circuitry. Curr Pharm Des (2012) 18:113-8. doi:10.2174/138161212798919110
17. Evidence-Based Approaches to Drug Addiction Treatment: Behavioral Therapies [Internet]. Bethesda, MD: National Institute on Drug Abuse (US) (2014). Available from: http://www.drugabuse.gov/publications/principles-drug-addiction-treatment/evidence-based-approaches-to-drug-addiction-treatment/behavioral-therapies
18. Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology (2013) 38:1557-65. doi:10.1038/npp.2013.54
19. Balter RE, Cooper ZD, Haney M. Novel pharmacologic approaches to treating cannabis use disorder. Curr Addict Rep (2014) 1:137-43. doi:10.1007/s40429-014-0011-1
20. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology (2012) 37:1689-98. doi:10.1038/npp.2012.14
21. McClure EA, Sonne SC, Winhusen T, Carroll KM, Ghitza UE, McRae-Clark AL, et al. Achieving cannabis cessation - evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials (2014) 39:211-23. doi:10.1016/j.cct.2014.08.011
22. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized controlled trial. JAMA Intern Med (2014) 174:70-7. doi:10.1001/jamainternmed.2013.11950
23. Jobes ML, Ghitza UE, Epstein DH, Phillips KA, Heishman SJ, Preston KL. Clonidine blocks stress-induced craving in cocaine users. Psychopharmacology (Berl) (2011) 218:83-8. doi:10.1007/s00213-011-2230-7
24. Fox H, Sinha R. The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals. Adv Pharmacol (2014) 69:217-65. doi:10.1016/B978-0-12-420118-7.00006-8
25. Sinha R, Kimmerling A, Doebrick C, Kosten TR. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology (Berl) (2007) 190:569-74. doi:10.1007/s00213-006-0640-8
26. U.S. Food and Drug Administration (FDA). Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. Silver Spring, MD: FDA (2012).
27. Ghitza UE, Tai B. Challenges and opportunities for integrating preventive substance-use-care services in primary care through the Affordable Care Act. J Health Care Poor Underserved (2014) 25:36-45. doi:10.1353/hpu.2014.0067